cigna glp-1 2025 dropping obesity drug coverage for employees (CI) cigna glp-1 news cigna glp

Glucagon-like peptide-1 receptor agonists show promise for reducing apnea-hypopnea index and body weight in patients with obstructive sleep apnea, offering new treatment options beyond PAP therapy.

However, experiencing debilitating nausea or vomiting should not be part of your weight or diabetes management journey

The booming GLP-1 market, projected to reach $167bn by 2031, presents compelling opportunities for private equity players to carve out their niche and capture substantial value, despite industry giants Novo Nordisk and Eli Lilly dominating the lions share of the market. Download PDF

In summary, it contains: Probiotic Blend: (Clostridium butyricum WB-STR-0006,Akkermansia muciniphila WB-STR-0001,Bifidobacterium infantis), Chicory inulin

The survival benefit was more pronounced in younger people and those with cardiometabolic comorbidities, highlighting the need for a careful riskbenefit evaluation when prescribing GLP-1 RAs in high-risk individuals.